Tweet
Clin Exp Immunol
. 2023 Jun 14;uxad066.
doi: 10.1093/cei/uxad066. Online ahead of print. Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals
Pradeep D Pushpakumara 1 , Chandima Jeewandara 1 , Farha Bary 1 , Deshan Madushanka 1 , Lahiru Perera 1 , Inoka Sepali Aberathna 1 , Thashmi Nimasha 1 , Jeewantha Jayamali 1 , Thushali Ranasinghe 1 , Heshan Kuruppu 1 , Saubhagya Danasekara 1 , Ananda Wijewickrama 2 , Graham S Ogg 3 , Gathsaurie Neelika Malavige 1 3
Affiliations
As there are limited data on B cell epitopes for the nucleocapsid protein in SARS-CoV-2, we sought to identify the immunodominant regions within the N protein, recognized by patients with varying severity of natural infection with the Wuhan strain (WT), delta, omicron and in those who received the Sinopharm vaccines, which is an inactivated, whole virus vaccine.Using overlapping peptides representing the N protein, with an in-house ELISA, we mapped the immunodominant regions within the N protein, in seronegative (n=30), WT infected (n=30), delta infected (n=30), omicron infected+vaccinated (n=20) and Sinopharm (BBIBP-CorV) vaccinees (n=30). We then investigated the sensitivity and specificity of these immunodominant regions and analysed their conservation with other SARS-CoV-2 variants of concern, seasonal human coronaviruses and bat Sarbecoviruses. We identified four immunodominant regions aa 29-52, aa 155-178, aa 274 to 297 and aa 365 to 388, were highly conserved within SARS-CoV-2 and the bat coronaviruses. The magnitude of responses to these regions varied based on the infecting SARS-CoV-2 variants, >80% of individuals gave responses above the positive cut-off threshold to many of the four regions, with some differences with individuals who were infected with different VoCs. These regions were found to be 100% specific, as none of the seronegative individuals gave any responses. As these regions were highly specific with high sensitivity, they have a potential to be used to develop diagnostic assays and to be used in development of vaccines.
Keywords: ELISA; SARS-COv-2; Sinopharm; conservation; immunodominant; nucleocapsid protein; overlapping peptides; sarbecoviruses; variants.
. 2023 Jun 14;uxad066.
doi: 10.1093/cei/uxad066. Online ahead of print. Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals
Pradeep D Pushpakumara 1 , Chandima Jeewandara 1 , Farha Bary 1 , Deshan Madushanka 1 , Lahiru Perera 1 , Inoka Sepali Aberathna 1 , Thashmi Nimasha 1 , Jeewantha Jayamali 1 , Thushali Ranasinghe 1 , Heshan Kuruppu 1 , Saubhagya Danasekara 1 , Ananda Wijewickrama 2 , Graham S Ogg 3 , Gathsaurie Neelika Malavige 1 3
Affiliations
- PMID: 37313783
- DOI: 10.1093/cei/uxad066
As there are limited data on B cell epitopes for the nucleocapsid protein in SARS-CoV-2, we sought to identify the immunodominant regions within the N protein, recognized by patients with varying severity of natural infection with the Wuhan strain (WT), delta, omicron and in those who received the Sinopharm vaccines, which is an inactivated, whole virus vaccine.Using overlapping peptides representing the N protein, with an in-house ELISA, we mapped the immunodominant regions within the N protein, in seronegative (n=30), WT infected (n=30), delta infected (n=30), omicron infected+vaccinated (n=20) and Sinopharm (BBIBP-CorV) vaccinees (n=30). We then investigated the sensitivity and specificity of these immunodominant regions and analysed their conservation with other SARS-CoV-2 variants of concern, seasonal human coronaviruses and bat Sarbecoviruses. We identified four immunodominant regions aa 29-52, aa 155-178, aa 274 to 297 and aa 365 to 388, were highly conserved within SARS-CoV-2 and the bat coronaviruses. The magnitude of responses to these regions varied based on the infecting SARS-CoV-2 variants, >80% of individuals gave responses above the positive cut-off threshold to many of the four regions, with some differences with individuals who were infected with different VoCs. These regions were found to be 100% specific, as none of the seronegative individuals gave any responses. As these regions were highly specific with high sensitivity, they have a potential to be used to develop diagnostic assays and to be used in development of vaccines.
Keywords: ELISA; SARS-COv-2; Sinopharm; conservation; immunodominant; nucleocapsid protein; overlapping peptides; sarbecoviruses; variants.